Houssam Zazgad

Direttore operativo presso PROMETHERA Biosciences SA

Health Technology

Profilo

Houssam Zazgad currently works as the Chief Operating Officer & Director at PROMETHERA Biosciences SA. He is currently working as a Director at Hepatic Cell Therapy Support SA since 2020.

Posizioni attive di Houssam Zazgad

Società	Posizione	Inizio
Hepatic Cell Therapy Support SA Hepatic Cell Therapy Support SA BiotechnologyHealth Technology Part of Catalent, Inc., Hepatic Cell Therapy Support SA is a cell therapy manufacturing facility. The company is based in Charleroi, Belgium. Founded in 2011, the Belgian company operates as a cell therapy manufacturing facility. Hepatic Cell Therapy Support was acquired by Catalent, Inc. from PROMETHERA Biosciences SA on May 06, 2021 for $18.25 million.	Direttore/Membro del Consiglio	15/09/2020
PROMETHERA Biosciences SA PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.	Direttore operativo	-

Tutte le posizioni attive di Houssam Zazgad

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Houssam Zazgad

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
PROMETHERA Biosciences SA PROMETHERA Biosciences SA Pharmaceuticals: MajorHealth Technology PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.	Health Technology
Hepatic Cell Therapy Support SA Hepatic Cell Therapy Support SA BiotechnologyHealth Technology Part of Catalent, Inc., Hepatic Cell Therapy Support SA is a cell therapy manufacturing facility. The company is based in Charleroi, Belgium. Founded in 2011, the Belgian company operates as a cell therapy manufacturing facility. Hepatic Cell Therapy Support was acquired by Catalent, Inc. from PROMETHERA Biosciences SA on May 06, 2021 for $18.25 million.	Health Technology